Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technical analysis for shorts & longs -- Ignore unavailable to you. Want to Upgrade?

To: Johnny Canuck who wrote (40547)	12/30/2003 8:40:49 PM
From: Johnny Canuck	Read Replies (1) \| Respond to of 69263

MULTEX ABRIDGED BUSINESS SUMMARY Nanogen, Inc. develops and commercializes molecular diagnostics products and tests for the gene-based testing market for sale primarily in the United States, Europe and the Pacific Rim. By integrating microelectronics and molecular biology into a core proprietary technology platform, the Company seeks to establish the open-architecture design of its primary products, the NanoChip Molecular Biology Workstation and the NanoChip Cartridge (collectively, the NanoChip System) as the standard platform for molecular identification and analysis. Nanogen also develops analyte specific reagents and other commercial applications for the NanoChip System. The Company continually conducts research and development, by itself and with its subsidiary and third parties, to improve the NanoChip System and to extend its technology to other applications such as biodefense, forensics and drug discovery (protein kinases). [Harry: I would anticipate that actual therpaies are years away. I would alos expect that the diagnostic abilities are a double edge sword. Knowing you have the potential for a serious disease and not having a cure present an ethical dilemma and may have less of a benefit to the patient. At this point it is more a tool for insurance companies to denie coverage.]